PreprintCited by 897Epigenetics and DNA MethylationChromatin Remodeling and CancerGenomics and Chromatin Dynamics

The DOI matches its Crossref record; 64 of the 68 references it cites were found in a registry or an index.

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells

Open access

Tan, Jing, Yang, Xiaojing, Zhuang, Li, Jiang, Xia, Chen, Wei, Lee, Puay Leng, Karuturi, R.K. Murthy, Tan, Patrick Boon Ooi, Liu, Edison T., Yu, Qiang·2007·Genes & Development

DOI 10.1101/gad.1524107PMC PMC1855231

Open this paper in CoChat — free account Open PDF

Abstract

Polycomb-repressive complex 2 (PRC2)-mediated histone methylation plays an important role in aberrant cancer gene silencing and is a potential target for cancer therapy. Here we show that S-adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanocin A (DZNep) induces efficient apoptotic cell death in cancer cells but not in normal cells. We found that DZNep effectively depleted cellular levels of PRC2 components EZH2, SUZ12, and EED and inhibited associated histone H3 Lys 27 methylation (but not H3 Lys 9 methylation). By integrating RNA interference (RNAi), genome-wide expression analysis, and chromatin immunoprecipitation (ChIP) studies, we have identified a prominent set of genes selectively repressed by PRC2 in breast cancer that can be reactivated by DZNep. We further demonstrate that the preferential reactivation of a set of these genes by DZNep, including a novel apoptosis affector, FBXO32 , contributes to DZNep-induced apoptosis in breast cancer cells. Our results demonstrate the unique feature of DZNep as a novel chromatin remodeling compound and suggest that pharmacologic reversal of PRC2-mediated gene repression by DZNep may constitute a novel approach for cancer therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1101/gad.1524107

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Histone methylation by the Drosophila epigenetic transcriptional regulator Ash1
Beisel, C., Imhof, A., Greene, J., Kremmer, E., & Sauer, F. (2002) · Nature · doi:10.1038/nature01126 · Cited by 310
Retracted
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
Regulation of chromatin structure by site-specific histone H3 methyltransferases
Rea, S., Eisenhaber, F., O'Carroll, D., Strahl, B. D., Sun, Z.-W., Schmid, M., Opravil, S., Mechtler, K., Ponting, C. P., Allis, C. D., et al. (2000) · Nature · doi:10.1038/35020506 · Cited by 2,845 · cited 1×
“In contrast, histone H3 trimethylation at Lys 9 (H3-K9me3)—which is mediated by another histone MTase, Suv39h1 (Rea et al. 2000; Peters et al. 2001; Lehnertz et al. 2003)—was not affected by DZNep treatment.”
Background
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Polycomb complexes repress developmental regulators in murine embryonic stem cells
Boyer, L. A., Plath, K., Zeitlinger, J., Brambrink, T., Medeiros, L. A., Lee, T. I., Levine, S. S., Wernig, M., Tajonar, A., Ray, M. K., et al. (2006) · Nature · doi:10.1038/nature04733 · Cited by 2,568
The history of cancer epigenetics
Feinberg, A. P., & Tycko, B. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1279 · Cited by 2,404
Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells
Lee, T. I., Jenner, R. G., Boyer, L. A., Guenther, M. G., Levine, S. S., Kumar, R., Chevalier, B. S., Johnstone, S. E., Cole, M. F., Isono, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.043 · Cited by 2,296
The Polycomb group protein EZH2 directly controls DNA methylation
Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204

Show all 68 references

Sorted by citations

Items 301–400 of 897

Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2
Huang, W.-Y., Yang, P., Chang, Y.-F., Márquez, V. E., & Chen, C. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.11.014 · Cited by 62
Derivation of new human embryonic stem cell lines reveals rapid epigenetic progression in vitro that can be prevented by chemical modification of chromatin
Perez, S. V. D., Kim, R., Li, Z., Márquez, V. E., Patel, S. G., Plath, K., & Clark, A. T. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr506 · Cited by 56
Lung Cancer Therapy Targeting Histone Methylation: Opportunities and Challenges
Chen, Y., Liu, X., Li, Y., Quan, C., Zheng, L., & Huang, K. (2018) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.06.001 · Cited by 62
Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges
Gold, S. R., & Shilatifard, A. (2024) · Journal of Clinical Investigation · doi:10.1172/jci183391 · Cited by 59
Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma
Yamaguchi, J., Sasaki, M., Sato, Y., Itatsu, K., Harada, K., Zen, Y., Ikeda, H., Nimura, Y., Nagino, M., & Nakanuma, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01387.x · Cited by 60
S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells
Liu, T., Lo, H.-L., Wei, L.-S., Hsiao, H. H.-Y., & Yang, P. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000166 · Cited by 59
MicroRNA-26a Is Strongly Downregulated in Melanoma and Induces Cell Death through Repression of Silencer of Death Domains (SODD)
Reuland, S. N., Smith, S. M., Bemis, L., Goldstein, N. B., Almeida, A. R., Partyka, K. A., Márquez, V. E., Zhang, Q., Norris, D. A., & Shellman, Y. G. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.400 · Cited by 59
Histone methyltransferases: regulation of transcription and contribution to human disease
Nimura, K., Ura, K., & Kaneda, Y. (2010) · Journal of Molecular Medicine · doi:10.1007/s00109-010-0668-4 · Cited by 61
Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential
Sun, R., Shen, J. K., Gao, Y., Zhou, Y., Yu, Z., Hornicek, F. J., Kan, Q., & Duan, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.9518 · Cited by 63
Targeting EZH2 as cancer therapy
Hanaki, S., & Shimada, M. (2021) · The Journal of Biochemistry · doi:10.1093/jb/mvab007 · Cited by 56
A Potent, Selective CBX2 Chromodomain Ligand and Its Cellular Activity During Prostate Cancer Neuroendocrine Differentiation
Wang, S., Alpsoy, A., Sood, S., Ordonez‐Rubiano, S. C., Dhiman, A., Sun, Y., Jiao, G., Krusemark, C. J., & Dykhuizen, E. C. (2021) · ChemBioChem · doi:10.1002/cbic.202100118 · Cited by 60
EZH2-mediated development of therapeutic resistance in cancer
Kaur, P., Shankar, E., & Gupta, S. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216706 · Cited by 64
Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder
Wang, H., Albadine, R., Magheli, A., Guzzo, T. J., Ball, M. W., Hinz, S., Schoenberg, M., Netto, G. J., & Gonzalgo, M. L. (2011) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.09.005 · Cited by 58
Histones and Their Modifications in Ovarian Cancer – Drivers of Disease and Therapeutic Targets
Marsh, D. J., Shah, J. S., & Cole, A. J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00144 · Cited by 58
EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer
Chen, J., Hong, J. H., Huang, Y., Liu, S., Yin, J., Deng, P., Sun, Y.-C., Yu, Z., Zeng, X., Xiao, R., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01786-y · Cited by 57
Self-citation
Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma
Lv, Y., Yan, G., Meng, G., Zhang, X., & Guo, Q. (2015) · Scientific Reports · doi:10.1038/srep12999 · Cited by 58
Role of Epigenetic Modifications in Luminal Breast Cancer
Abdel-Hafiz, H. A., & Horwitz, K. B. (2015) · Epigenomics · doi:10.2217/epi.15.10 · Cited by 59
Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression
Pang, J. C., Toy, K. A., Griffith, K. A., Awuah, B., Quayson, S. E., Newman, L. A., & Kleer, C. G. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2055-z · Cited by 57
Naturally occurring anti-cancer agents targeting EZH2
Shahabipour, F., Caraglia, M., Majeed, M. A., Derosa, G., Maffioli, P., & Sahebkar, A. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.020 · Cited by 61
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Yan, X., Zhang, S., Deng, Y., Wang, P., Hou, Q., & Xu, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01050 · Cited by 59
A Sequence Polymorphism in miR-608 Predicts Recurrence after Radiotherapy for Nasopharyngeal Carcinoma
Zheng, J., Deng, J., Xiao, M., Yang, L., Zhang, L., You, Y., Hu, M., Li, N., Wu, H., Li, W., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0395 · Cited by 56
EZH 2: an emerging role in melanoma biology and strategies for targeted therapy
Tiffen, J. C., Gallagher, S. J., & Hersey, P. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12280 · Cited by 58
Molecular Epigenetics and Genetics in Neuro-Oncology
Nagarajan, R. P., & Costello, J. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.04.002 · Cited by 57
Disruption of the epigenetic code: An emerging mechanism in mental retardation
van Bokhoven, H., & Kramer, J. M. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.03.010 · Cited by 59
Dysregulation of the Repressive H3K27 Trimethylation Mark in Head and Neck Squamous Cell Carcinoma Contributes to Dysregulated Squamous Differentiation
Gannon, O. M., de Long, L. M., Endo‐Munoz, L., Hazar-Rethinam, M. H., & Saunders, N. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2505 · Cited by 58
Control of fluxes in metabolic networksPreprint
Basler, G., Nikoloski, Z., Larhlimi, A., Barabási, A.-Ĺ., & Liu, Y.-Y. (2016) · Genome Research · doi:10.1101/gr.202648.115 · Cited by 54
Remodeling of Ca2+ signaling in cancer: Regulation of inositol 1,4,5-trisphosphate receptors through oncogenes and tumor suppressors
Ando, H., Kawaai, K., Bonneau, B., & Mikoshiba, K. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.12.001 · Cited by 55
The various regulatory functions of long noncoding RNAs in apoptosis, cell cycle, and cellular senescence
Asl, M. H., Khelejani, F. P., Mahdavi, S. Z. B., Emrahi, L., Jebelli, A., & Mokhtarzadeh, A. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30221 · Cited by 58
EZH2 Down-Regulation Exacerbates Lipid Accumulation and Inflammation in in Vitro and in Vivo NAFLD
Vella, S., Gnani, D., Crudele, A., Ceccarelli, S., Stefanis, C. D., Gaspari, S., Nobili, V., Locatelli, F., Márquez, V. E., Rota, R., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141224154 · Cited by 55
Epigenetic drugs against cancer: an evolving landscape
Costanzo, A. D., Gaudio, N. D., Migliaccio, A., & Altucci, L. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1315-6 · Cited by 54
MicroRNAs in rhabdomyosarcoma: pathogenetic implications and translational potentiality
Rota, R., Ciarapica, R., Giordano, A., Miele, L., & Locatelli, F. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-120 · Cited by 55
Chromatin maps, histone modifications and leukemia
Neff, T., & Armstrong, S. A. (2009) · Leukemia · doi:10.1038/leu.2009.40 · Cited by 54
Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer
Zeller, C., & Brown, R. E. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010375759 · Cited by 56
Epigenetic regulation in RCC: opportunities for therapeutic intervention?
Larkin, J., Goh, X. Y., Vetter, M. H. F., Pickering, L. M., & Swanton, C. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2011.236 · Cited by 57
Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management
Chan, T. A.-T., Ho, A. S., & Turcan, Ş. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s34680 · Cited by 54
Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs
Gelato, K. A., Adler, D., Ocker, M., & Haendler, B. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1134490 · Cited by 52
3-Deazaneplanocin A (DZNep), an Inhibitor of S-Adenosylmethionine-dependent Methyltransferase, Promotes Erythroid Differentiation
Fujiwara, T., Saitoh, H., Inoue, A., Kobayashi, M., Okitsu, Y., Katsuoka, Y., Fukuhara, N., Onishi, Y., Ishizawa, K., Ichinohasama, R., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.548651 · Cited by 53
PRAJA1 is a ubiquitin ligase for the polycomb repressive complex 2 proteins
Zoabi, M., Sadeh, R., de Bie, P., & Ciechanover, A. J. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.025 · Cited by 54
Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy
Huang, C., Huang, S., Pao, J.-B., Chang, T.-Y., Lan, Y. ‐., Lu, T., Lee, H.-Z., Juang, S., Wu, P., Pu, Y., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr264 · Cited by 53
X-Chromosome Inactivation in Rett Syndrome Human Induced Pluripotent Stem Cells
Cheung, A. Y. L., Horvath, L. M., Carrel, L., & Ellis, J. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00024 · Cited by 56
Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation
Momparler, R. L., Idaghdour, Y., Márquez, V. E., & Momparler, L. F. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.03.001 · Cited by 54
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients
Crea, F., Fornaro, L., Paolicchi, E., Masi, G., Frumento, P., Loupakis, F., Salvatore, L., Cremolini, C., Schirripa, M., Graziano, F., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr387 · Cited by 52
ALDH1A1 Is a Novel EZH2 Target Gene in Epithelial Ovarian Cancer Identified by Genome-Wide Approaches
Li, H., Bitler, B. G., Vathipadiekal, V., Maradeo, M. E., Slifker, M. J., Creasy, C. L., Tummino, P. J., Cairns, P., Birrer, M. J., & Zhang, R. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0414 · Cited by 52
Polycomb Repressive Complex 2 Silences Human Cytomegalovirus Transcription in Quiescent Infection Models
Abraham, C. G., & Kulesza, C. A. (2013) · Journal of Virology · doi:10.1128/jvi.02420-13 · Cited by 58
Praja1 E3 ubiquitin ligase promotes skeletal myogenesis through degradation of EZH2 upon p38α activation
Consalvi, S., Brancaccio, A., Dall’Agnese, A., Puri, P., & Palacios, D. (2017) · Nature Communications · doi:10.1038/ncomms13956 · Cited by 52
Gene mutations and molecularly targeted therapies in acute myeloid leukemia.
Hatzimichael, E. C., Georgiou, G. K., Benetatos, L., & Briasoulis, E. C. (2013) · Europe PMC (PubMed Central) · Cited by 50
Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer
Chen, H.-M., Gao, S., Li, J., Liu, D., Sheng, C., Yao, C., Jiang, W., Wu, J., Chen, S., & Huang, W. (2015) · Oncotarget · doi:10.18632/oncotarget.3790 · Cited by 51
Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase
Ott, M., Litzenburger, U. M., Sahm, F., Rauschenbach, K. J., Tudoran, R., Hartmann, C. J., Márquez, V. E., von Deimling, A., Wick, W., & Platten, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047663 · Cited by 55
Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics
Khan, F. S., Ali, I., Afridi, U. K., Ishtiaq, M., & Mehmood, R. (2016) · Hepatology International · doi:10.1007/s12072-016-9743-4 · Cited by 52
Targeting histone methylation for colorectal cancer
Huang, T., Lin, C., Zhong, L. L. D., Zhao, L., Zhang, G., Lü, A., Wu, J., & Bian, Z. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16671287 · Cited by 51
−7/7q− syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity
Honda, H., Nagamachi, A., & Inaba, T. (2014) · Oncogene · doi:10.1038/onc.2014.196 · Cited by 50
YC ‐1 inhibits proliferation of breast cancer cells by down‐regulating EZH 2 expression via activation of c‐ C bl and ERK
Chang, L., Lin, H., Tsai, M., Chou, R., Lee, F., Teng, C., Hsieh, M., Hung, H., Huang, L., Yu, Y., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12708 · Cited by 50
Epigenetic targets and drug discovery
Liu, Y., Liu, K., Su, Q., Xu, C., & Min, J. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.03.007 · Cited by 51
Ribavirin as a tri-targeted antitumor repositioned drug
la Cruz-Hernández, E. N. D., Medina‐Franco, J. L., Trujillo, J. E., Chávez-Blanco, A. D., Domínguez-Gómez, G., Pérez‐Cárdenas, E., González‐Fierro, A., Taja‐Chayeb, L., & Dueñas‐González, A. (2015) · Oncology Reports · doi:10.3892/or.2015.3816 · Cited by 51
Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells
Benoit, Y. D., Witherspoon, M., Laursen, K. B., Guezguez, A., Beauséjour, M., Beaulieu, J., Lipkin, S. M., & Gudas, L. J. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.04.006 · Cited by 50
Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma
Teider, N., Scott, D. K., Neiss, A., Weeraratne, S. D., Amani, V. M., Wang, Y., Márquez, V. E., Cho, Y., & Pomeroy, S. L. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq091 · Cited by 50
Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients
Liu, F., Gu, L., Cao, Y. J., Fan, X., Zhang, F., & Sang, M. (2015) · Biomarkers · doi:10.3109/1354750x.2015.1118537 · Cited by 50
Role of EZH2 histone methyltrasferase in melanoma progression and metastasis
Mahmoud, F. A., Shields, B. D., Makhoul, I., Hutchins, L. F., Shalin, S. C., & Tackett, A. J. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1167291 · Cited by 53
The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells
Miele, E., Valente, S., Alfano, V., Silvano, M., Mellini, P., Borovika, D., Marrocco, B., Pò, A., Besharat, Z. M., Catanzaro, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19782 · Cited by 49
Genome Architecture Facilitates Phenotypic Plasticity in the Honeybee (Apis mellifera)
Duncan, E. J., Leask, M., & Dearden, P. K. (2020) · Molecular Biology and Evolution · doi:10.1093/molbev/msaa057 · Cited by 47
EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis
Liu, H., Li, W., Yu, X., Gao, F., Duan, Z., Ma, X., Tan, S., Yuan, Y., Liu, L., Wang, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10841 · Cited by 50
OTX2 sustains a bivalent-like state of OTX2-bound promoters in medulloblastoma by maintaining their H3K27me3 levels
Bunt, J., Hasselt, N. E., Zwijnenburg, D. A., Köster, J., Versteeg, R., & Kool, M. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1069-2 · Cited by 49
Inhibition of PRC2 histone methyltransferase activity increases TRAIL‐mediated apoptosis sensitivity in human colon cancer cells
Benoit, Y. D., Laursen, K. B., Witherspoon, M., Lipkin, S. M., & Gudas, L. J. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24224 · Cited by 49
Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers
Yang, Y., Kim, H., Li, W., & Kong, A. T. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150826114359 · Cited by 52
EZH2 inhibitors: a patent review (2014-2016)
Stazi, G., Zwergel, C., Mai, A., & Valente, S. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1316976 · Cited by 49
Epigenetic Targets and their Inhibitors in Cancer Therapy
Zhao, L., Duan, Y., Lü, P., Zhang, Z., Zheng, X., Wang, J., & Feng, W. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666181224095449 · Cited by 52
Haploinsufficiency of the murine polycomb gene Suz12 results in diverse malformations of the brain and neural tube
Miró, X., Zhou, X., Boretius, S., Michaelis, T., Kubisch, C., Álvarez-Bolado, G., & Gruß, P. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.001602 · Cited by 49
The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines
Prystowsky, M. B., Adomako, A., Smith, R. V., Kawachi, N., McKimpson, W. M., Atadja, P. W., Chen, Q., Schlecht, N. F., Parish, J. L., Childs, G. J., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2554 · Cited by 48
Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells
Nakagawa, S., Sakamoto, Y., OKABE, H., Hayashi, H., Hashimoto, D., Yokoyama, N., Tokunaga, R., Sakamoto, K., Kuroki, H., Mima, K., et al. (2013) · Oncology Reports · doi:10.3892/or.2013.2922 · Cited by 48
Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells
Fiskus, W. C., Rao, R., Balusu, R., Ganguly, S., Tao, J., Sotomayor, E. M., Mudunuru, U., Smith, J. E., Hembruff, S. L., Atadja, P. W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0873 · Cited by 49
Epigenetic Modifications in Prostate Cancer
Ngollo, M., Dagdemir, A., Karslı-Çeppioğlu, S., Judes, G., Pajon, A., Penault-Llorca, F. M., Boiteux, J., Bignon, Y., Guy, L., & Bernard-Gallon, D. J. (2014) · Epigenomics · doi:10.2217/epi.14.34 · Cited by 48
Emerging Role of SOX Proteins in Breast Cancer Development and Maintenance
Mehta, G., Khanna, P., & Gatza, M. L. (2019) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-019-09430-6 · Cited by 51
The Polycomb Group Protein EZH2 Impairs DNA Damage Repair Gene Expression in Human Uterine Fibroids1
Yang, Q., Nair, S., Laknaur, A., Ismail, N., Diamond, M. P., & Al-Hendy, A. A. (2016) · Biology of Reproduction · doi:10.1095/biolreprod.115.134924 · Cited by 47
20(S)-Ginsenoside Rh2 suppresses proliferation and migration of hepatocellular carcinoma cells by targeting EZH2 to regulate CDKN2A-2B gene cluster transcription
Li, Q., Bai, L., Dong, C., Wang, Y., & Li, Q. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.09.023 · Cited by 47
Epigenomic profiling of cancer cells
Gargiulo, G., & Minucci, S. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.07.021 · Cited by 47
Clonogenic Multiple Myeloma Cells have Shared stemness Signature Associated with Patient Survival
Reghunathan, R., Bi, C., Liu, S. C., Koh, T.-L., Chung, T., Huang, G., & Chng, W. J. (2013) · Oncotarget · doi:10.18632/oncotarget.1145 · Cited by 46
Small-molecular modulators of cancer-associated epigenetic mechanisms
Itoh, Y., Suzuki, T., & Miyata, N. (2013) · Molecular BioSystems · doi:10.1039/c3mb25410k · Cited by 46
Deregulated Expression of the Polycomb-Group Protein SUZ12 Target Genes Characterizes Mantle Cell Lymphoma
Martín-Pérez, D., Sánchez, E., Maestre, L., Suela, J., Vargiu, P., Lisio, L. D., Martı́nez, N., Alves, J., Piris, M. A., & Sánchez‐Beato, M. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090769 · Cited by 46
Toxicogenomics-Based Identification of Mechanisms for Direct Immunotoxicity
Shao, J., Katika, M. R., Schmeits, P. C. J., Hendriksen, P. J. M., Loveren, H. V., Peijnenburg, A., & Volger, O. L. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft151 · Cited by 46
Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies
Maury, E., & Hashizume, R. (2017) · Epigenetics · doi:10.1080/15592294.2016.1278095 · Cited by 50
Histone methylation‐mediated silencing of miR‐139 enhances invasion of non‐small‐cell lung cancer
Watanabe, K., Amano, Y., Ishikawa, R., Sunohara, M., Kage, H., Ichinose, J., Sano, A., Nakajima, J., Fukayama, M., Yatomi, Y., et al. (2015) · Cancer Medicine · doi:10.1002/cam4.505 · Cited by 45
Epigenetic regulation of prostate cancer
Chin, P. S., Dickinson, J. L., & Holloway, A. F. (2011) · Clinical Epigenetics · doi:10.1007/s13148-011-0041-7 · Cited by 45
Role of epigenetic mechanisms in epithelial-to-mesenchymal transition of breast cancer cells
Nickel, A., & Stadler, S. C. (2014) · Translational research · doi:10.1016/j.trsl.2014.04.001 · Cited by 44
Epigenetic silencing of microRNA-218 via EZH2-mediated H3K27 trimethylation is involved in malignant transformation of HBE cells induced by cigarette smoke extract
Wang, B., Liu, Y., Luo, F., Xu, Y., Qin, Y., Lü, X., Xu, W., Shi, L., Liu, Q., & Xiang, Q. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1435-z · Cited by 45
Current Limitations And Future Opportunities For Epigenetic Therapies
Cherblanc, F., Chapman‐Rothe, N., Brown, R. E., & Fuchter, M. J. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.7 · Cited by 44
Global Epigenetic Profiling In Bladder Cancer
Dudziec, E., Goepel, J. R., & Catto, J. W. F. (2011) · Epigenomics · doi:10.2217/epi.10.71 · Cited by 43
Targeting EZH2 regulates tumor growth and apoptosis through modulating mitochondria dependent cell-death pathway in HNSCC
Zhou, X., Ren, Y., Kong, L., Cai, G., Sun, S., Song, W., Wang, Y., Jin, R., Qi, L., Mei, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5606 · Cited by 45
EZH2 inhibitors transcriptionally upregulate cytotoxic autophagy and cytoprotective unfolded protein response in human colorectal cancer cells.
Hsieh, Y., Lo, H.-L., & Yang, P. (2016) · Europe PMC (PubMed Central) · Cited by 45
Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1
McNiel, E. A., & Tsichlis, P. N. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.45 · Cited by 45
Targeting the epigenome in malignant pleural mesothelioma
McLoughlin, K. C., Kaufman, A. S., & Schrump, D. S. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.06.06 · Cited by 45
Polycomb Repressor Complex 2 in Genomic Instability and Cancer
Veneti, Z., Gkouskou, K. K., & Eliopoulos, A. G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081657 · Cited by 49
Dynamic Patterns of Histone Lysine Methylation in the Developing Retina
Rao, R. C., Tchedre, K. T., Malik, M. T., Coleman, N. L., Fang, Y., Márquez, V. E., & Chen, D. F. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4730 · Cited by 46
A potential antitumor ellagitannin, davidiin, inhibited hepatocellular tumor growth by targeting EZH2
Wang, Y., Ma, J., Chow, S. C., Li, C. H., Xiao, Z., Feng, R., Fu, J., & Chen, Y. (2013) · Tumor Biology · doi:10.1007/s13277-013-1025-3 · Cited by 45
Heterochromatin dysregulation in human diseases
Hahn, M., Dambacher, S., & Schotta, G. (2010) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00053.2010 · Cited by 48
The Transcriptional Repressor ZBTB4 Regulates EZH2 Through a MicroRNA-ZBTB4-Specificity Protein Signaling Axis
Yang, W. S., Chadalapaka, G., Cho, S., Lee, S., Jin, U.-H., Jutooru, I., Choi, K., Leung, Y., Ho, S., Safe, S. H., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.09.011 · Cited by 44
DZNep inhibits H3K27me3 deposition and delays retinal degeneration in the rd1 mice
Zheng, S., Xiao, L., Liu, Y., Wang, Y., Cheng, L. Z., Zhang, J., Yan, N., & Chen, D. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0349-8 · Cited by 45
Targeting of cancer stem cells by inhibitors of DNA and histone methylation
Momparler, R. L., & Côté, S. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1051220 · Cited by 43
Tipping the lysine methylation balance in disease
Black, J. C., & Whetstine, J. R. (2012) · Biopolymers · doi:10.1002/bip.22136 · Cited by 47
HDAC1,2 inhibition impairs EZH2- and BBAP- mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma
Johnson, D. P., Spitz, G. S., Tharkar, S., Quayle, S. N., Shearstone, J. R., Jones, S. S., McDowell, M. E., Wellman, H., Tyler, J. K., Cairns, B. R., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3120 · Cited by 43
PRC2, Chromatin Regulation, and Human Disease: Insights From Molecular Structure and Function
Liu, X., & Liu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894585 · Cited by 48

Authors: Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., Karuturi, R. K. M., Tan, P. B. O., Liu, E. T., & Yu, Q.
Affiliations: Genome Institute of Singapore (SG)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Duke-NUS Medical School (SG)
ORCID: Tan, Jing
Yang, Xiaojing
Zhuang, Li
Jiang, Xia
Chen, Wei
Lee, Puay Leng
Karuturi, R.K. Murthy
Liu, Edison T.
Yu, Qiang
Venue: Genes & Development
Publisher: Cold Spring Harbor Laboratory
Published: 2007-04-16
Volume: 21
Issue: 9
Pages: 1050-1063
ISSN: 0890-9369 (ISSN-L)
1549-5477
DOI: 10.1101/gad.1524107
PMC: PMC1855231
OpenAlex: W2113634596
Cited by: 895
References: 68
Citations by year: 2026: 12 · 2025: 16 · 2024: 18 · 2023: 35 · 2022: 21 · 2021: 35 · 2020: 39 · 2019: 37 · 2018: 44 · 2017: 65 · 2016: 55 · 2015: 65 · 2014: 98 · 2013: 77 · 2012: 70
Type: posted content
Language: en
Open access: bronze
doi.org
Locations: Genes & Development (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
National University of Singapore (submittedVersion)
Funders: Agency for Science, Technology and Research
National Cancer Institute
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords: polycomb repressive complex 2, DZNep, EZH2, SUZ12, EED, histone H3 lysine 27 methylation, gene silencing, apoptosis, breast cancer, atrogin-1, chromatin remodeling, cancer therapy
MeSH terms: Adenosine, Base Sequence, Breast Neoplasms, Enzyme Inhibitors, Female, Histones, Humans, Methylation, Promoter Regions, Genetic, Repressor Proteins, RNA Polymerase II, Apoptosis, RNA Interference, RNA, Small Interfering, Chromatin Assembly and Disassembly, Adenosylhomocysteinase, Epigenesis, Genetic, Cell Line, Tumor, Chromatin Immunoprecipitation, Polycomb-Group Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks